摘要
慢性气道疾病是一类持续存在的呼吸系统疾病,对患者的生活质量和健康状况造成了严重影响,是全球公共卫生重要问题之一。瞬时受体电位锚蛋白亚型1(TRPA1)和瞬时受体电位香草酸亚型1(TRPV1)是2种重要的离子通道受体,两者活化参加气道平滑肌收缩、炎性介质释放、黏液分泌增加等反应,可引发气道炎性反应和气道高反应性等病理过程,在慢性气道疾病的发病机制中发挥着重要作用。因此,针对TRPV1和TRPA1的药物干预可能成为治疗慢性气道疾病的新策略。文章从发病机制和临床应用两方面展开综述,归纳总结TRPV1、TRPA1与慢性气道疾病的研究进展,以期为慢性气道疾病诊疗提供借鉴。
Chronic airway diseases(CADs)are a class of persistent respiratory diseases that have a serious impact on the quality of life and health status of patients,which are important issues in global public health.Transient receptor potential anchor protein subtype 1(TRPA1)and transient receptor potential vanilloid subtype 1(TRPV1)are ion channel receptors that play a significant role in the pathogenesis of CADS.The activation of TRPV1 and TRPA1 participates in airway smooth muscle contraction,release of inflammatory mediators,and increase in mucus secretion,which can trigger pathological processes such as airway inflammation and hyperresponsiveness.process.Therefore,pharmacological interventions targeting TRPV1 and TRPA1 may become a new strategy for the treatment of CADs.In order to further summaries the research progress of TRPV1,TRPA1 and CADs,this paper reviews the pathogenesis and clinical application of TRPV1 and TRPA1,with a view to providing a reference for the diagnosis and treatment of CADs.
作者
薛永新
何丹(综述)
陈炎城(审校)
Xue Yongxin;He Dan;Chen Yancheng(Department of Respiratory and Critical Care Medicine,Meizhou People's Hospital,Guangdong,Meizhou 514000,China)
出处
《疑难病杂志》
2025年第3期372-375,共4页
Chinese Journal of Difficult and Complicated Cases
基金
2022年度梅州市社会发展科技计划项目(20220B4)。
关键词
慢性气道疾病
瞬时受体电位锚蛋白亚型1
瞬时受体电位香草酸亚型1
发病机制
临床应用
Chronic airway diseases
Transient receptor potential anchor protein subtype 1
Transient receptor potential vanilloid subtype 1
Pathogenesis
Clinical application
